GENOCEA BIOSCIENCES, INC. (NASDAQ:GNCA) Files An 8-K Results of Operations and Financial Condition
Item 2.02
|
Results of Operations and Financial Condition.
|
announced its financial results for the first quarter ended March
31, 2017. A full text of the press release issued in connection
with the announcement is furnished as Exhibit 99.1 to this
Current Report on Form 8-K.
including Exhibit 99.1 attached hereto, is being furnished and
shall not be deemed filed for any purpose, and shall not be
deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Securities Exchange
Act of 1934, as amended, except as expressly set forth by
specific reference in such filing.
|
Item 7.01
|
Regulation FD Disclosure.
|
GEN-003 Phase 2 trial indicating an initial course of injections
sustains clinical and virologic efficacy for at least 24 months.
A full text of the press release issued in connection with the
announcement is furnished as Exhibit 99.1 to this Current Report
on Form 8-K.
including Exhibit 99.1 attached hereto, is being furnished and
shall not be deemed filed for any purpose, and shall not be
deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Securities Exchange
Act of 1934, as amended, except as expressly set forth by
specific reference in such filing.
|
Item 9.01
|
Financial Statements and Exhibits.
|
|
99.1
|
Press Release issued by Genocea Biosciences, Inc. on
May 4, 2017 |
About GENOCEA BIOSCIENCES, INC. (NASDAQ:GNCA)
Genocea Biosciences, Inc. is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment. It has one product candidate in Phase II clinical development: GEN-003, which is a therapeutic vaccine or immunotherapy for the treatment of genital herpes infections. It has pre-clinical development programs, which include GEN-001, which is indicated for the treatment of chlamydia prophylaxis, and GEN-002, which indicated for the treatment of genital herpes prophylaxis both of which are in pre-clinical stage of development. The Company’s pipeline also includes GEN-005, which is under malaria prophylaxis, Epstein-Barr virus and immuno-oncology programs in research stage of development. GENOCEA BIOSCIENCES, INC. (NASDAQ:GNCA) Recent Trading Information
GENOCEA BIOSCIENCES, INC. (NASDAQ:GNCA) closed its last trading session down -0.20 at 6.30 with 229,571 shares trading hands.
